SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
| ELONVA 150 mcg Solution For Injection | 150 µg | Solution for injection · Subcutaneous use | 1 Pre-filled syringe | SAR 2168.40 | NCE · Prescription | N.V. Organon | Valid |
| ELONVA 100 mcg Solution For Injection | 100 µg | Solution for injection · Subcutaneous use | 1 Pre-filled syringe | SAR 1436.35 | NCE · Prescription | N.V. Organon | Withdrawn by MAH · Not Marketed |
EMA European Union — centrally authorised medicines
Elonva Organon N.V. · Authorised · authorised 25 Jan 2010 · ATC G03GA09
Therapeutic indication (EMA)
Controlled Ovarian Stimulation (COS) in combination with a GnRH antagonist for the development of multiple follicles in women participating in an Assisted Reproductive Technology (ART) program. Elonva is indicated for the treatment of adolescent males (14 to less than 18 years and older) with hypogonadotropic hypogonadism, in combination with human Chorionic Gonadotropin (hCG).
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.